FDA Approves First CRISPR Gene Therapy for Sickle Cell Disease

On a Friday in early December, the FDA cleared two treatments that fundamentally reshape what medicine can do for sickle cell disease. One of them—Casgevy, made by Vertex Pharmaceuticals and Crispr Therapeutics—marks the first time the gene-editing tool CRISPR has been approved to treat human patients. The other, Lyfgenia from bluebird bio, uses an older gene therapy method. Both represent a threshold moment: the arrival of potential cures for a disease that has been systematically neglected by the pharmaceutical industry for decades.

Sickle cell affects roughly 100,000 Americans, with devastating disparity in who carries it. One in every 365 Black babies born in the United States will have the disease. It is caused by a genetic mutation that warps red blood cells into crescent shapes, which then lodge in blood vessels, starving organs of oxygen and triggering episodes of excruciating pain that can last for days. Until now, the only real hope for a cure was a bone marrow transplant—a procedure most patients couldn't access because finding a matching donor proved nearly impossible. For decades, people with sickle cell endured repeated hospitalizations, managed their pain with opioids, and organized their lives around the constant threat of crisis.

Johnny Lubin was one of the first to receive the CRISPR treatment as part of a clinical trial. Now 15 and living in Connecticut, he spent his first 13 years cycling through hospitals every few months. The pain, he recalls, was mostly in his lower back—a pounding sensation that made it hard to do ordinary things, to have fun, to be a kid. His parents kept a go bag packed at all times. In October 2021, Johnny received an infusion of his own cells, edited using CRISPR to reactivate the production of fetal hemoglobin, a form of the protein that babies naturally make in the womb. Since that single treatment, he has not had another pain crisis. His mother, Fabienne Desir, describes him now as living like a normal child. He swims without fear. His father is teaching him to drive. They mark the day of his infusion as his second birthday.

The science works by exploiting something the body already knows how to do. Fetal hemoglobin carries oxygen more efficiently than the mutated adult hemoglobin that causes sickle cell. By editing patients' cells to turn fetal hemoglobin production back on, doctors essentially recreate a state similar to sickle cell trait—a condition in which people inherit one sickle cell gene and one normal gene, and experience no symptoms. In the clinical trials, 29 of 30 patients remained free from pain crises for at least 12 months after treatment. The longest documented period without a crisis stretched to nearly four years. Researchers will continue following these patients, hoping the effects prove permanent.

But the approvals arrive shadowed by a question that may prove as consequential as the science itself: who will actually receive these treatments? Casgevy costs $2.2 million for the one-time procedure. Lyfgenia costs $3.1 million. These are not prices plucked from air—they reflect the genuine complexity of manufacturing a personalized therapy for each patient. Yet a pricing analysis group had suggested that $1.35 million to $2.05 million would have been cost-effective, and urged the companies to consider the lower end of that range. The treatments also demand infrastructure that exists only at large academic medical centers, typically in major cities. A physician in Illinois noted that the entire state outside Chicago has essentially no access. More than half of Americans with sickle cell depend on Medicaid for insurance. And the treatments themselves are not simple procedures—they require a month-long hospitalization, several days of chemotherapy to wipe out the bone marrow, and a recovery period during which patients are vulnerable to serious complications including infertility and, in rare cases documented in earlier trials, leukemia.

Dr. Lewis Hsu, chief medical officer for the Sickle Cell Disease Association of America, expressed the tension plainly: "I don't know whether it will get covered and paid for." Bluebird bio said it is in advanced discussions with major commercial insurers and Medicaid agencies representing 80 percent of the sickle cell population, and has designed payment structures tied to how well the therapy works over time. But the company also acknowledged that it has no plans to introduce this version of the treatment to Africa and India, where the majority of the world's sickle cell patients live, because the cost of manufacturing is prohibitive.

For Johnny Lubin and others like him, the transformation is undeniable and profound. He worried, before treatment, that he might develop superpowers. What he got instead was something more ordinary and more precious: the chance to be a teenager without constant fear, to swim in a pool all summer, to learn to drive. The approvals represent a vindication of decades of research and a rebuke to an industry that long ignored this disease. Yet they also pose a new question, one that will define whether this breakthrough becomes a cure for some or a reminder of how medicine's advances can deepen existing inequalities.